Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company.“Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “His expertise will help us advance a portfolio of targeted oncology agents, particularly AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors.”“I share the team’s passion to address the debilitating pain, deformity and,
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Piper Sandler from $23.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Immunome, Inc GAAP EPS of -$0.78 misses by $0.21 [Seeking Alpha]Seeking Alpha
- Immunome Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation ConferenceBusiness Wire
IMNM
Earnings
- 11/13/24 - Miss
IMNM
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMNM's page on the SEC website